Geoffrey R Oxnard

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
    Geoffrey R Oxnard
    Geoffrey R Oxnard, Ryan S Alden, Cloud P Paweletz, and Pasi A Jänne, Dana Farber Cancer Institute, Boston Kenneth S Thress and J Carl Barrett, AstraZeneca, Waltham, MA Rachael Lawrance and Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom and James Chih Hsin Yang, National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan
    J Clin Oncol 34:3375-82. 2016
  2. pmc Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
  3. pmc When progressive disease does not mean treatment failure: reconsidering the criteria for progression
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1234, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1534-41. 2012
  4. ncbi request reprint Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA
    Arch Pathol Lab Med 136:1205-9. 2012
  5. pmc Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
    Adrian G Sacher
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts2Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts
    JAMA Oncol 2:1014-22. 2016
  6. pmc Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
  7. pmc Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
    Cloud P Paweletz
    Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts
    Clin Cancer Res 22:915-22. 2016
  8. pmc Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
  9. doi request reprint Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
    Antonio Calles
    Department of Medical Oncology, Center for Immuno Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts and Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts
    J Thorac Oncol 10:1726-35. 2015
  10. pmc Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012

Collaborators

Detail Information

Publications41

  1. pmc Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
    Geoffrey R Oxnard
    Geoffrey R Oxnard, Ryan S Alden, Cloud P Paweletz, and Pasi A Jänne, Dana Farber Cancer Institute, Boston Kenneth S Thress and J Carl Barrett, AstraZeneca, Waltham, MA Rachael Lawrance and Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom and James Chih Hsin Yang, National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan
    J Clin Oncol 34:3375-82. 2016
    ..We studied whether noninvasive genotyping of cell-free plasma DNA (cfDNA) is a useful biomarker for prediction of outcome from a third-generation EGFR-TKI, osimertinib...
  2. pmc Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
    ..Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies...
  3. pmc When progressive disease does not mean treatment failure: reconsidering the criteria for progression
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1234, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1534-41. 2012
    ....
  4. ncbi request reprint Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA
    Arch Pathol Lab Med 136:1205-9. 2012
    ....
  5. pmc Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
    Adrian G Sacher
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts2Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts
    JAMA Oncol 2:1014-22. 2016
    ..Plasma genotyping of cell-free DNA has the potential to allow for rapid noninvasive genotyping while avoiding the inherent shortcomings of tissue genotyping and repeat biopsies...
  6. pmc Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
    ..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI...
  7. pmc Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
    Cloud P Paweletz
    Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts
    Clin Cancer Res 22:915-22. 2016
    ..To facilitate genotyping, we developed a next-generation sequencing (NGS) assay using a desktop sequencer to detect actionable mutations and rearrangements in cell-free plasma DNA (cfDNA)...
  8. pmc Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
    ..To examine this observation and define the course of patients following TKI discontinuation, we systematically evaluated patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib...
  9. doi request reprint Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
    Antonio Calles
    Department of Medical Oncology, Center for Immuno Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts and Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts
    J Thorac Oncol 10:1726-35. 2015
    ..We aimed to determine the expression profile of PD-1 and its ligands, PD-L1 and PD-L2, in both smokers and never smokers patients with KRAS-mutant NSCLC...
  10. pmc Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
    ..We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations...
  11. pmc New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 17:5530-7. 2011
    ..In this review, we discuss recent advances in the understanding of acquired TKI resistance in EGFR-mutant lung cancer and review therapeutic progress with second generation TKIs and combinations of targeted therapies...
  12. pmc Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer
    Peter C Lo
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer 121:2570-7. 2015
    ..Anecdotal experience suggests that this drug may provide continued disease control after patients develop objective progression of disease (PD), although this has not been systematically studied to date...
  13. pmc Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung
    Andrew M Brunner
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women s Hospital, Boston, Massachusetts and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    J Thorac Oncol 8:1434-7. 2013
    ..An open-label phase II trial with dasatinib was carried out to determine the response rates in patients with SqCC who had previously failed standard chemotherapy and to correlate responses with patient genotype...
  14. pmc Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
    ..In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI...
  15. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  16. pmc Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
    Magda Bahcall
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer Discov 6:1334-1341. 2016
    ..Based on these findings, the patient was treated with erlotinib combined with cabozantinib, a type II MET inhibitor, and exhibited a response...
  17. ncbi request reprint A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
    Masahiko Yanagita
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Clin Cancer Res . 2016
    ..Circulating tumor cell (CTC) or cell-free DNA (cfDNA) analysis may allow for noninvasive evaluation. This prospective trial evaluated CTCs and cfDNA in EGFR-mutant NSCLC patients treated with erlotinib until progression...
  18. doi request reprint Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
    Antonio Calles
    Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Clin Cancer Res 21:2851-60. 2015
    ..We validated an IHC assay for LKB1 loss and determined the impact of LKB1 loss in KRAS-mutant non-small cell lung cancer (NSCLC)...
  19. pmc Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
    Hiroyuki Yasuda
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Sci Transl Med 5:216ra177. 2013
    ..Our studies reveal intricate differences between EGFR mutations, their biology, and their response to EGFR TKIs. ..
  20. pmc Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 78:161-6. 2012
    ..Compare the clinical characteristics, rate of recurrent venous thromboembolism (VTE) and outcome of suspected and unsuspected pulmonary embolism (PE) detected on computed tomography in patients with lung cancer...
  21. doi request reprint MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
    Mark M Awad
    Mark M Awad, Geoffrey R Oxnard, David M Jackman, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, and Peter S Hammerman, Dana Farber Cancer Institute Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Pasi A Jänne, Peter S Hammerman, and Lynette M Sholl, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Suman Verma, ResearchDX, Irvine and James Christensen, Mirati Therapeutics, San Diego, CA
    J Clin Oncol 34:721-30. 2016
    ..We sought to describe the clinical, pathologic, and genomic characteristics of patients with cancer with MET exon 14 mutations...
  22. pmc Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
    Geoffrey R Oxnard
    Authors Affiliations Department of Medical Oncology Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 20:1698-705. 2014
    ..We sought to determine whether droplet digital PCR (ddPCR) of cfDNA would allow highly specific and quantitative assessment of tumor genotype...
  23. pmc Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
    Kenneth S Thress
    AstraZeneca, Gatehouse Park, Waltham, Massachusetts, USA
    Nat Med 21:560-2. 2015
    ..Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation. ..
  24. pmc Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development
    Benjamin L Lampson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer . 2016
    ..The recommended dose of 150 mg daily is the maximum tolerated dose (MTD). Few clinical data are available regarding its efficacy at doses less than the MTD...
  25. pmc Clinical Implications of Variant ALK FISH Rearrangement Patterns
    Xin Gao
    Brigham and Women s Hospital, Boston, Massachusetts and Dana Farber Cancer Institute, Boston, Massachusetts
    J Thorac Oncol 10:1648-52. 2015
    ..We hypothesized that there may be clinical differences depending on rearrangement pattern on FISH...
  26. pmc Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer
    Adrian G Sacher
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts2Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts
    JAMA Oncol 2:313-20. 2016
    ..Herein, we report on the association of young age with targetable genomic alterations and prognosis in a cohort of 2237 patients with NSCLC...
  27. doi request reprint Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA, USA Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA, USA Electronic address
    Lancet Oncol 15:1433-41. 2014
    ..We did a trial of dacomitinib as initial systemic therapy in clinically and molecularly selected patients with advanced non-small-cell lung cancer...
  28. doi request reprint Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer
    Ravi B Parikh
    Harvard Medical School, Boston, Massachusetts
    Int J Radiat Oncol Biol Phys 89:880-7. 2014
    ....
  29. pmc Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Oncologist 18:1214-20. 2013
    ..We observed an improved response rate but no difference in progression-free survival or overall survival. A larger prospective clinical trial is needed to evaluate this promising strategy further. ..
  30. pmc Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Clin Cancer Res 19:1634-6. 2013
    ..In the accompanying article, the authors carried out a meta-analysis of the published literature on EGF receptor (EGFR) genotype and erlotinib/gefitinib sensitivity to develop a publicly accessible database to inform patient care...
  31. pmc New targetable oncogenes in non-small-cell lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 31:1097-104. 2013
    ....
  32. ncbi request reprint Non-small cell lung cancer in octogenarians: treatment practices and preferences
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Thorac Oncol 2:1029-35. 2007
    ..Treatment practices in this patient population are poorly described. In this report, we describe the treatment of a population of very elderly patients with NSCLC at a large teaching hospital...
  33. pmc Enhanced ratio of signals enables digital mutation scanning for rare allele detection
    Elena Castellanos-Rizaldos
    Division of DNA Repair and Genome Stability, Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    J Mol Diagn 17:284-92. 2015
    ..COLD-ddPCR enables a simple, rapid, and robust two-fluorophore detection method for the identification of multiple mutations during ddPCR and potentially can identify unknown DNA variants present in the target sequence. ..
  34. ncbi request reprint Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
    Geoffrey R Oxnard
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 24:392-9. 2010
    ..Currently active trials are referenced using their ClinicalTrials.gov identifier...
  35. doi request reprint Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials
    Ryan S Alden
    Dana Farber Cancer Institute, Boston, MA, USA
    Chin Clin Oncol 4:37. 2015
    ..Thus, ALCHEMIST is a platform for validation of targeted therapy as part of curative care in NSCLC and creates an opportunity to advance our understanding of disease biology. ..
  36. doi request reprint Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    JAMA Oncol 2:772-9. 2016
    ..Objective response rate (ORR) is an increasingly important end point for accelerated development of highly active anticancer therapies, yet its relationship to regulatory approval is not well characterized...
  37. pmc Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Department of Epidemiology and Biostatistics, Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA Department of Medicine, Vanderbilt Ingram Cancer Center, Franklin, TN and Lowe center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA
    J Thorac Oncol 10:431-7. 2015
    ..To better understand the impact of KRAS mutation subtype, we analyzed data from 677 patients with KRAS mutant metastatic lung cancer...
  38. pmc Institutional implementation of clinical tumor profiling on an unselected cancer population
    Lynette M Sholl
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    JCI Insight 1:e87062. 2016
    ..b>FUNDING. This work was supported by DFCI, BWH, and the National Cancer Institute (5R33CA155554 and 5K23CA157631)...
  39. doi request reprint Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
    Junko Tanizaki
    Lowe Center for Thoracic Oncology, Boston, Massachusetts Department of Medical Oncology, Boston, Massachusetts
    Cancer Res 75:3139-46. 2015
    ..Our findings provide a rationale for therapeutically targeting this unique subset of FGFR2-mutant cancers as well as insight into their oncogenic mechanisms...
  40. pmc Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer
    Adrian G Sacher
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada
    Cancer 120:2289-98. 2014
    ..Emerging data from trials of third-generation mutant-specific EGFR kinase inhibitors suggests particular promise with this class of agents...
  41. ncbi request reprint Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, USA
    Lung Cancer 52:141-8. 2006
    ..Application of the RECIST response criteria to mesothelioma thickness measurements yields PR and PD classifications based on smaller volume changes than for spherical tumors...